Alfentanil
Usage
Structure
Analogue of fentanyl
Pharmacodynamics
Potency
Less potent than fentanyl
* About 1/10 to 1/5 the potency as fentanyl
* About 1/3 the duration as fentanyl
Effects
PONV
At equipotent doses of alfentanil, sufentanil, and fentanyl,
* Alfentanil is associated with lower incidence of PONV compared to sufentanil and fentanyl
Biliary spasm
Similar increase in biliary tract pressures as that produced by fentanyl
* But shorter in duration
Pharmacokinetics
Absorption
Distribution
- Vd
= 27 L [SH4:p93]
= 0.4-1.0 L/kg [RDM6:p401]
- Protein-binding
= 92% [SH4:p93; RDM6:p401]
* Principally bound to alpha1-acid glycoprotein (level is not altered by liver disease)
- Alfentanil has smaller Vd than fentanyl (3-5L/kg) because
* Lower lipid solubility (129 vs 955), AND
* Higher protein-binding (92% vs 84%)
Metabolism
- Hepatic extraction ratio
= 0.3 - 0.5 [RDM6:p401]
Metabolism is mainly by two independent pathways
- Piperidine N-dealkylation
--> Noralfentanil
- Amide N-dealkylation
--> N-phenylpropionamide
- Noralfentanil is the major metabolite recovered in urine
- Metabolism of alfentanil is mainly by CYP450 3A4
* Alfentanil is a sensitive probe for CYP3A activity
Elimination
- Clearance
= 4 - 9 mL/kg/min [RDM6:p401]
- <0.5% of alfentanil is excreted unchanged in urine.
- 96% of alfentanil is cleared from plasma within 60 minutes
Action profile
- Effect-site equilibration time = 1.4 min
* c.f. fentanyl (6.8min) and sufentanil (6.2min)
* Fast equilibration time is due to low pKa (6.5), and thus high proportion (90%) is unionised, despite lower lipid solubility
- Elimination half-time = 1.4-1.5 hours
* c.f. fentanyl (3.1-6.6 hours) and sufentanil (2.2-4.6 hours)
- Context sensitive half-time after 4 hours of infusion = 60 min
* c.f. sufentanil (30 min)
* CSHT for alfentanil is fairly constant after 4 hours [???]
- Duration of action = 5-10 min
* [SS3:p10]
Alfentanil vs sufentanil
Alfentanil has smaller Vd than sufentanil
--> Vd of alfentanil equilibrates more quickly than sufentanil
--> Peripheral distribution is not a significant contributor to decreases in plasma concentration of alfentanil
--> Even though alfentanil has shorter half-life than sufentanil, but after 4 hours of infusion, half-time becomes longer than sufentanil
Physicochemical properties
- Weak base
- pKa = 6.5
--> 89% non-ionised at pH 7.4
* Lowest pK of opioids
- Partition coefficient = 129
* When morphine = 1
* c.f. Sufentanil (1727) and fentanil (955)
Pharmaceutics
Clinical
Administration
Intubation
- Alfentanil 15 microgram/kg about 90 seconds before laryngoscopy
--> Blunts the systemic BP and HR response to intubation
Induction of anaesthesia
- Alfentanil 150-300 microgram/kg
--> Unconsciousness in 45 seconds
Interaction
- Erythromycin inhibits alfentanil metabolism by its action on CYP450 enzymes
Caution
Untreated Parkinson's disease
- Alfentanil may cause acute dystonia in patients with untreated Parkinson's diease
- Alfentanil may decrease central dopaminergic transmission
Special considerations
Hepatic impairment
- Liver cirrhosis prolongs the elimination half-time of alfentanil
- Cholestatic disease does NOT prolong the elimination half-time
Renal impairment
- Renal failure does NOT alter the clearance or elimination half-time of alfentanil
Paediatrics
- In children, alfentanil has shorter elimination half-time
* Smaller Vd in children, thus faster elimination
* Smaller Vd due to smaller percentage of adipose tissues